Cancer

J-Pharma drives first cancer LAT1 to phase III study with FDA nod

Tue, 23 Jun 2026 12:00:00 -0400

J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat (JPH‑203), in a global phase III Beacon-BTC study of biliary tract cancer following U.S. FDA alignment.

EFPIA report: Every €1 spent on new drugs returns €5.67 to Europe’s economy

Tue, 23 Jun 2026 12:00:00 -0400

The industry is stepping up its campaign to persuade European governments to increase their drugs budgets, in what is described as a landmark report making the case that spending on patented drugs is not a cost to be contained, but an investment in health and the economy.

China approves first CAR T for solid tumors

Tue, 23 Jun 2026 12:00:00 -0400

China’s National Medical Products Administration approved Carsgen Therapeutics Holdings Ltd.’s NDA for satricabtagene autoleucel (satri-cel, CT-041), marking the first global approval of a CAR T therapy for solid tumors. The autologous Claudin18.2-targeted CAR T was approved for patients with Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy.

Pfizer ADC, from Seagen M&A, fails in phase III NSCLC trial

Tue, 23 Jun 2026 12:00:00 -0400

Missing statistical significance on the primary overall survival phase III endpoint with antibody-drug conjugate (ADC) sigvotatug vedotin compared with docetaxel in non-small-cell lung cancer (NSCLC), Pfizer Inc., which gained the candidate through its $43 billion buyout of Seagen Inc. in 2023, is forging ahead based on subgroup signals, phase I data and an ongoing phase III Keytruda combination effort currently underway.

K2 nabs two Antengene bispecific TCEs in $2B license, option deal

Tue, 23 Jun 2026 09:00:00 -0400

MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan.

Rin Institute discovers new insoluble fibrin-targeting ADCs

Tue, 23 Jun 2026 09:00:00 -0400

Rin Institute Inc. has disclosed antibody-drug conjugates consisting of an antibody targeting insoluble fibrin conjugated to MMAE through a plasmin-cleavable linker reported to be useful for the treatment of cancer.

EVmiR-885-5p limits TNBC spread in preclinical models

Mon, 22 Jun 2026 09:00:00 -0400

Researchers at Theramir Ltd. presented preclinical proof-of-concept data for a new extracellular vesicle (EV) platform engineered to deliver miR-885-5p (EVmiR885-5p), targeting leukocyte-specific protein-1 (LCP-1)-mediated cytoskeletal remodeling in triple-negative breast cancer (TNBC) models.

CATA-001 yields promising results for light chain multiple myeloma

Mon, 22 Jun 2026 09:00:00 -0400

Light chain multiple myeloma (LCMM) is a cancer driven by malignant plasma cells that produce excessive pathogenic free light chains (FLCs) that may cause kidney dysfunction and form amyloid deposits in key organs, thus leading to poor outcomes. Ab Studio Inc.’s CATA-001 is a bispecific antibody targeting both CD38 and aggregated light chains (ALs) designed to deplete CD38+ plasma cells and clear both circulating and tissue-deposited pathogenic FLC aggregates for the treatment of LCMM and AL amyloidosis.

K2 nabs two Antengene bispecific TCEs in $2B license, option deal

Mon, 22 Jun 2026 09:00:00 -0400

Nankai University and Accendatech present new majusculamide D derivatives